Unraveling ANKTIVA’s Triangle Offense: Exploring with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat on UroToday Podcast
Today, ImmunityBio has announced the release of three podcasts in collaboration with UroToday, shedding light on the recent FDA approval of ANKTIVA® (N-803, also known as nogapendekin alfa inbakicept-pmln) alongside…
NADclinic and Bontac Bio-Engineering Form Strategic Partnership to Advance Global Wellness with NAD+
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have forged a robust strategic alliance aimed at shaping the future landscape of global health and wellness. Drawing upon their respective proficiencies…
Report on Reproductive Hormones and Proteins Testing Markets: 2015-2024 & 2033
The latest addition to ResearchAndMarkets.com’s offerings is the “Reproductive Hormones and Proteins Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033” report. This insightful analysis delves into…
Marinus Pharmaceuticals Unveils Significant Developments for Tuberous Sclerosis Complex Program
Aiming to advance treatment options for seizure disorders, Marinus Pharmaceuticals has successfully completed enrollment in the global Phase 3 TrustTSC trial. This trial assesses oral ganaxolone’s efficacy in managing seizures…
Azitra, Inc. Reveals Promising Preclinical Results for ATR-04 at Society of Investigative Dermatology Annual Meeting
Azitra, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering innovative therapies for precision dermatology, has unveiled preclinical findings from its cutting-edge platform and pipeline. These findings are being presented at…
WHO Revises List of Drug-Resistant Bacteria Posing Greatest Threat to Human Health
The World Health Organization (WHO) has unveiled its updated Bacterial Priority Pathogens List (BPPL) for 2024, highlighting 15 families of antibiotic-resistant bacteria grouped into critical, high, and medium categories for…
BioNTech SE Shareholders Approve All Proposals at 2024 Annual General Meeting
BioNTech SE (Nasdaq: BNTX), referred to as “BioNTech” or the “Company,” held its Annual General Meeting (AGM) on May 17, 2024. The virtual assembly saw representation from 87.51% of the…
AbbVie Showcases New Data Supporting Premier Gastroenterology Portfolio at 2024 Digestive Disease Week
AbbVie (NYSE: ABBV) announced it will present 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, occurring May 18-21 in Washington, D.C., and virtually. “At DDW, AbbVie is…
Understanding the Difference Between IBS and IBD
Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are often confused, as their names and symptoms—such as diarrhea and abdominal pain—are similar. However, these gastrointestinal (GI) disorders are fundamentally…
Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction and Safety
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials for once-weekly insulin efsitora alfa (efsitora) in adults with type 2…
Nucleai Names Vikas Ahuja as VP of Strategic Partnerships, Driving Diagnostic Deployment and Scale-Up
A spatial AI biomarker company specializing in deciphering cellular conversations and mapping cellular interactions within tissue samples to predict therapeutic outcomes has announced the expansion of its executive leadership team.…
Accenture’s Investment in Turbine to Boost AI-Powered Cell Simulations for Biopharma R&D
Accenture Ventures, a strategic arm of Accenture (NYSE: ACN), recently announced its investment in Turbine, a forward-thinking predictive simulation company dedicated to interpreting human biology. This investment aims to bolster…